Shanghai Jianxin Biopharmaceutical Technology

Shanghai Jianxin Biopharmaceutical Technology is a clinical-stage biotechnology company focused on the discovery and development of next-generation bispecific and multispecific antibody therapeutics for oncology. The company leverages its proprietary antibody engineering platforms to create molecules that can simultaneously target multiple immune checkpoints or tumor-associated antigens. Its lead candidate, JX-08, is a bispecific antibody targeting PD-L1 and 4-1BB designed to enhance anti-tumor immune responses while minimizing systemic toxicity. Jianxin Bio aims to address unmet medical needs in patients with advanced solid tumors through innovative immunotherapy combinations. The company is headquartered in Shanghai's Zhangjiang Hi-Tech Park and is backed by prominent venture capital firms including Sequoia China and Matrix Partners China.